Coronary artery bypass grafting statins should be taken for a long time, but the incidence of adverse reactions associated with statins is very low. As long as the drugs are used reasonably and the adverse reactions are monitored, statins are indeed a very safe class of lipid-lowering drugs. Statins are not only the most effective LDL-C-lowering drugs available, but also the only lipid-lowering drugs that reduce overall mortality in patients with coronary artery disease. Statin-induced myopathy is rare in clinical practice, and statin-induced myopathy often presents as nonspecific muscle pain or arthralgia. There is a correlation between statin application and elevated liver enzyme levels, and it is well established that this is a class effect of statins, i.e., all currently marketed statins may have this adverse effect. There are no definitive data on the incidence of statin-induced increases in transaminase levels, and it is generally believed that less than 1-2% of all patients treated with statins experience an increase in transaminase levels to more than 3 times the upper limit of normal, and that transaminase levels decrease after discontinuation of the drug.